Mannatech (MTEX) Stock Price, News & Analysis

Company Overview

Mannatech, Inc. is a global nutrition company specializing in the development, manufacture and marketing of dietary supplements and personal care products through a direct selling business model. Since its founding in 1993 in Texas, the company has focused on research-backed formulations centered on glyconutrient technology—complex carbohydrates believed to support cellular communication. Its flagship supplement, Ambrotose®, is designed to promote gastrointestinal health and overall wellness.

In addition to its core nutritional offerings, Mannatech’s product portfolio includes skin and body care lines formulated with proprietary botanical extracts and peptides. The Cerule line targets anti-aging and hydration, while the AgeLOC™ series integrates science-driven approaches to support skin resilience and youthfulness. Mannatech also offers targeted products for immune support, weight management and fitness recovery, enabling the company to address a broad spectrum of consumer health needs.

Mannatech distributes its products through a network of independent associates across North America, Europe, Asia, Latin America and the Middle East. This direct selling approach is supplemented by e-commerce platforms, allowing the company to tailor its distribution strategies to regional preferences and regulations. Over the years, Mannatech has expanded its manufacturing capabilities and established partnerships with third-party laboratories to ensure product quality and compliance with international standards.

Leadership at Mannatech emphasizes scientific research and global expansion. Kevin Guest, who was appointed Chief Executive Officer in 2021, brings extensive experience in consumer products and international operations. The executive team collaborates with a scientific advisory board to guide product innovation and clinical validation efforts. Headquartered in Flower Mound, Texas, Mannatech continues to invest in research initiatives and strategic partnerships to drive long-term growth and deliver health and wellness solutions to customers around the world.

Key Stats

• Today's Range: $8.50 to $8.80
• 50-Day Range: $8.41 to $11.97
• 52-Week Range: $7.00 to $16.49
• Volume: 3,424 shs
• Average Volume: 6,042 shs
• Market Capitalization: $16.16 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mannatech Stock Analysis - MarketRank™

Mannatech scored higher than 28% of companies evaluated by MarketBeat, and ranked 895th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mannatech.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mannatech is -85.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mannatech is -85.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mannatech has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.58% of the float of Mannatech has been sold short.

Short Interest Ratio / Days to Cover

Mannatech has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mannatech has recently decreased by 12.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Mannatech does not currently pay a dividend.

Dividend Growth

Mannatech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.58% of the float of Mannatech has been sold short.

Short Interest Ratio / Days to Cover

Mannatech has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mannatech has recently decreased by 12.70%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Mannatech has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Mannatech this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mannatech insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.50% of the stock of Mannatech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.98% of the stock of Mannatech is held by institutions.

MTEX Stock Analysis - Frequently Asked Questions

How have MTEX shares performed this year?

Mannatech's stock was trading at $13.43 at the start of the year. Since then, MTEX shares have decreased by 36.7% and is now trading at $8.50.

How were Mannatech's earnings last quarter?

Mannatech, Incorporated (NASDAQ:MTEX) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.80) EPS for the quarter. The business earned $26.56 million during the quarter. Mannatech had a negative net margin of 0.19% and a negative trailing twelve-month return on equity of 2.56%.

How do I buy shares of Mannatech?

Shares of MTEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mannatech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mannatech investors own include CrowdStrike (CRWD), Walt Disney (DIS), Herbalife (HLF), Roku (ROKU), Alibaba Group (BABA), Enphase Energy (ENPH) and Enterprise Products Partners (EPD).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MTEX
• CIK: 1056358
• Web: www.mannatech.com
• Phone: (972) 471-7400
• Fax: 972-471-8117
• Employees: 250
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $2.49 million
• Net Margins: -0.19%
• Pretax Margin: 0.61%
• Return on Equity: -2.56%
• Return on Assets: -0.57%

Debt

• Debt-to-Equity Ratio: 0.46
• Current Ratio: 1.18
• Quick Ratio: 0.65

Sales & Book Value

• Annual Sales: $117.87 million
• Price / Sales: 0.14
• Cash Flow: $2.09 per share
• Price / Cash Flow: 4.07
• Book Value: $4.57 per share
• Price / Book: 1.86

Miscellaneous

• Outstanding Shares: 1,900,000
• Free Float: 1,112,000
• Market Cap: $16.15 million
• Optionable: Not Optionable
• Beta: 0.89